A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir

Abstract During the ongoing pandemic, providing treatment consisting of effective, low-cost oral antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling COVID-19. Although Paxlovid and molnupiravir have received emergency approval from the FDA, some side effect...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Yumin Zhang, Yuan Sun, Yuanchao Xie, Weijuan Shang, Zhen Wang, Hualiang Jiang, Jingshan Shen, Gengfu Xiao, Leike Zhang
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Nature Publishing Group 2023-09-01
Σειρά:	Signal Transduction and Targeted Therapy
Διαθέσιμο Online:	https://doi.org/10.1038/s41392-023-01587-1
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!